Details for New Drug Application (NDA): 211724
✉ Email this page to a colleague
The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 211724
| Tradename: | CAPECITABINE |
| Applicant: | Reliance Life |
| Ingredient: | capecitabine |
| Patents: | 0 |
Pharmacology for NDA: 211724
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 211724
Suppliers and Packaging for NDA: 211724
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | capecitabine | TABLET;ORAL | 211724 | ANDA | Lifestar Pharma LLC | 70756-815 | 70756-815-60 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (70756-815-60) |
| CAPECITABINE | capecitabine | TABLET;ORAL | 211724 | ANDA | Lifestar Pharma LLC | 70756-816 | 70756-816-22 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (70756-816-22) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Apr 27, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Apr 27, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
